Discovery and Optimization of 2-Arylquinazolin-4-ones into a Potent and Selective Tankyrase Inhibitor Modulating Wnt Pathway Activity.


Journal

Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531

Informations de publication

Date de publication:
12 09 2019
Historique:
pubmed: 6 8 2019
medline: 1 7 2020
entrez: 6 8 2019
Statut: ppublish

Résumé

Tankyrases 1 and 2 (TNKS1/2) are promising pharmacological targets that recently gained interest for anticancer therapy in Wnt pathway dependent tumors. 2-Aryl-quinazolinones were identified and optimized into potent tankyrase inhibitors through SAR exploration around the quinazolinone core and the 4'-position of the phenyl residue. These efforts were supported by analysis of TNKS X-ray and WaterMap structures and resulted in compound

Identifiants

pubmed: 31381853
doi: 10.1021/acs.jmedchem.9b00656
doi:

Substances chimiques

Enzyme Inhibitors 0
Quinazolines 0
arylquinazolin-4-one 0
TNKS2 protein, human EC 2.4.2.30
Tankyrases EC 2.4.2.30
TNKS protein, human EC 2.4.4.30

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

7897-7909

Auteurs

Hans-Peter Buchstaller (HP)

Merck Healthcare KGaA , Global Research & Development , Frankfurter Strasse 250 , 64293 Darmstadt , Germany.

Uwe Anlauf (U)

Merck Healthcare KGaA , Global Research & Development , Frankfurter Strasse 250 , 64293 Darmstadt , Germany.

Dieter Dorsch (D)

Merck Healthcare KGaA , Global Research & Development , Frankfurter Strasse 250 , 64293 Darmstadt , Germany.

Daniel Kuhn (D)

Merck Healthcare KGaA , Global Research & Development , Frankfurter Strasse 250 , 64293 Darmstadt , Germany.

Martin Lehmann (M)

Merck Healthcare KGaA , Global Research & Development , Frankfurter Strasse 250 , 64293 Darmstadt , Germany.

Birgitta Leuthner (B)

Merck Healthcare KGaA , Global Research & Development , Frankfurter Strasse 250 , 64293 Darmstadt , Germany.

Djordje Musil (D)

Merck Healthcare KGaA , Global Research & Development , Frankfurter Strasse 250 , 64293 Darmstadt , Germany.

Daniela Radtki (D)

Merck Healthcare KGaA , Global Research & Development , Frankfurter Strasse 250 , 64293 Darmstadt , Germany.

Claudio Ritzert (C)

Merck Healthcare KGaA , Global Research & Development , Frankfurter Strasse 250 , 64293 Darmstadt , Germany.

Felix Rohdich (F)

Merck Healthcare KGaA , Global Research & Development , Frankfurter Strasse 250 , 64293 Darmstadt , Germany.

Richard Schneider (R)

Merck Healthcare KGaA , Global Research & Development , Frankfurter Strasse 250 , 64293 Darmstadt , Germany.

Christina Esdar (C)

Merck Healthcare KGaA , Global Research & Development , Frankfurter Strasse 250 , 64293 Darmstadt , Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH